Mochida wins new drug approval for Epadel S in China

Japanese drugmakers Mochida Pharmaceutical (TYO: 4534) and Marubeni Pharmaceutical announced that Mochida has obtained new drug approval from the China National Medical Products Administration (NMPA) for Epadel S900 (MND-21), a highly purified eicosapentaenoic acid (EPA) ethyl ester formulation developed in China by Mochida and Marubeni Pharma for the treatment of severe hypertriglyceridemia.

Mochida has entered into a distribution agreement with Meiji for the marketing of Epadel in China. Following this approval, Mochida will supply the product to Meiji, which will distribute it through its affiliated partner in China, MAXMIND Bio-Technology (Hainan)d. In addition, Mochida will provide support, including the provision of information, to MAXMIND Bio-Technology (Hainan) Co through Meiji.

Mochida and Meiji have entered into a contract for the sale of Epadel in the ASEAN region, including Thailand and Vietnam, and Taiwan. As of today, Epadel is being sold in Thailand, and preparations are underway for its launch in Vietnam. Going forward, Mochida, Meiji, and Marubeni Pharma will work together to deliver EPADEL S® to patients in China and contribute to improving their quality of life.